Biocom - Life Sciences Association of California
San Diego  |   Los Angeles  |   Washington, DC  |   Tokyo

Vertex Pharmaceuticals Partnering Forum

Monday, July 10 2017 - Monday, July 10 2017
4:00 PM - 7:00 PM

Add to Calendar America/Los_Angeles Vertex Pharmaceuticals Partnering Forum

Representatives from Vertex Pharmaceuticals will be in San Diego on July 10th to meet with representatives from local academic institutions, research organizations, venture capital firms, and companies with programs and technologies complementary to Vertex Pharmaceutical's pipeline and capabilities. Please join us for a plenary session and networking reception from 4:00 PM - 7:00 PM. Space is limited and registration is required. 

The Alexandria at Torrey Pines Biocom false MM/DD/YYYY

The Alexandria at Torrey Pines
10996 Torreyana Road
San Diego, CA 92121
Registration Deadline:
Monday, July 10 2017
4:00 PM

Biocom Hosts Vertex Pharmaceuticals Partner Day in San Diego 

One of Biocom’s most valuable roles is as facilitator for our member companies, which takes many forms. Biocom Partner Days is one of those programs. This program brings buyers and sellers together to discuss partnerships, licensing opportunities and/or M&A deals. Companies are selected for one-on-one meetings through an application process, where the selection committee will identify companies that best fit the partnering strategy. Accepted companies are scheduled in meetings/presentations with the company executives. We invite you to apply and are now accepting company applications - see below for details. Also, please join us for a presentation and a networking reception on July 10th from 4:00 PM - 7:00 PM. Space is limited and registration is required. 

Vertex Partner Day

Vertex is a global biotechnology company investing in scientific innovation to create transformative medicines for serious and life-threatening diseases. Vertex discovered, developed and now sells the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to active clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.  We are a team of 2,100 people in the United States, Europe, Canada and Australia with nearly two-thirds of our staff dedicated to research and development.
To achieve our goal of creating transformative medicines to treat or cure diseases with a high-unmet medical need, we seek external partnerships that promote scientific innovation and provide clinical solutions. We believe innovation should be focused on creating mutually respectful and beneficial corporate relationships grounded in deep biological knowledge of the disease and target.

Our current corporate partnering priorities include:

  • Building upon our deep understanding and presence in cystic fibrosis
  • Diversifying our portfolio with transformative medicines in rare diseases including:
    • Adrenoleukodystrophy
    • Alpha-1 antitrypsin deficiency
    • Sickle Cell Disease
    • Duchenne Muscular Dystrophy
    • Spinal Muscular Atrophy
    • Autosomal Dominant Polycystic Kidney disease
    • as well as considering programs with strong biological rationale or clinical data
  • Leveraging cutting-edge technology platforms to accelerate the discovery of new disease targets, compounds, delivery mechanisms and treatment modalities

How to Apply:

If you are interested in meeting with the Vertex Pharmaceuticals Business Development team on July 11th, please send over a one-page non-confidential executive summary for review to Oscar Rodarte at by June 26th for consideration.

In Partnership With:

 User-added image



Oscar Rodarte

Sponsored By: